A detailed history of M28 Capital Management LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, M28 Capital Management LP holds 161,600 shares of TGTX stock, worth $4.05 Million. This represents 3.31% of its overall portfolio holdings.

Number of Shares
161,600
Previous 161,600 -0.0%
Holding current value
$4.05 Million
Previous $2.46 Million 16.97%
% of portfolio
3.31%
Previous 2.31%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$13.02 - $21.3 $716,100 - $1.17 Million
-55,000 Reduced 25.39%
161,600 $2.46 Million
Q3 2023

Nov 13, 2023

BUY
$8.36 - $26.5 $619,476 - $1.96 Million
74,100 Added 52.0%
216,600 $1.81 Million
Q2 2023

Aug 11, 2023

SELL
$15.48 - $35.0 $3.05 Million - $6.9 Million
-197,000 Reduced 58.03%
142,500 $3.54 Million
Q1 2023

May 12, 2023

BUY
$10.23 - $19.34 $2.41 Million - $4.55 Million
235,100 Added 225.19%
339,500 $5.11 Million
Q4 2022

Feb 10, 2023

SELL
$5.01 - $11.83 $1.17 Million - $2.77 Million
-234,400 Reduced 69.19%
104,400 $1.24 Million
Q3 2022

Nov 10, 2022

SELL
$4.57 - $8.4 $1.77 Million - $3.25 Million
-387,400 Reduced 53.35%
338,800 $2.01 Million
Q2 2022

Aug 12, 2022

SELL
$3.74 - $10.66 $1.2 Million - $3.43 Million
-321,700 Reduced 30.7%
726,200 $3.09 Million
Q1 2022

May 13, 2022

BUY
$7.81 - $20.45 $4.07 Million - $10.7 Million
520,900 Added 98.84%
1,047,900 $9.97 Million
Q4 2021

Feb 11, 2022

BUY
$15.2 - $35.51 $8.01 Million - $18.7 Million
527,000 New
527,000 $10 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $3.64B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track M28 Capital Management LP Portfolio

Follow M28 Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M28 Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on M28 Capital Management LP with notifications on news.